{"id":4536,"date":"2018-09-18T15:04:01","date_gmt":"2018-09-18T15:04:01","guid":{"rendered":"https:\/\/www.maatpharma.com\/?p=4536"},"modified":"2025-11-26T14:50:49","modified_gmt":"2025-11-26T12:50:49","slug":"maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic","status":"publish","type":"post","link":"https:\/\/www.maatpharma.com\/fr\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/","title":{"rendered":"黑料社 Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic"},"content":{"rendered":"

Results from in silico<\/em> analysis using 黑料社\u2019s data analysis platform, GutPrint, demonstrate therapeutic rationale and manufacturing capabilities of developing a high diversity biological drug product<\/h3>\n

Lyon, France, September 18, 2018<\/strong> \u2013 黑料社 announced today the presentation of the analysis of 黑料社\u2019s lead biotherapeutic, MaaT013, demonstrating its drug product characteristics using 黑料社\u2019s proprietary big data analysis platform, GutPrint\u00ae<\/span>. The results of the study form the foundation of 黑料社\u2019s approach to create standardized and reproducible high diversity microbiome therapeutics to treat life-threatening diseases. 黑料社\u2019s Bioinformatics Manager, Lilia Boucinha, Ph.D. presented the data at the 2018 European Molecular Biology Organization (EMBO) Symposium \u2013 The Human Microbiome, being held from September 16 \u2013 19, 2018 at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.In the presented study 黑料社\u2019s proprietary biotherapeutic MaaT013 was evaluated in comparison to a single donor approach using 黑料社\u2019s proprietary and validated big data analysis platform GutPrint\u00ae<\/span>. In comparison to single donor samples, MaaT013 showed significantly increased diversity. Most importantly, diversity within the sample batches was less variable and a greater homogeneity between batches was observed compared to single donor samples. Furthermore, the analysis of the MaaT013 samples showed that there was a 58% increase in the number of microbes (richness) compared to single-donor-based FMT products and less than 5% of Proteobacteria, which are known to include pro-inflammatory species. Taken together, these data strongly highlight 黑料社\u2019s capabilities to produce a cGMP high diversity drug product for clinical evaluation.Poster Discussion Session details:<\/strong><\/p>\n

Title<\/strong>: Developing a New Generation of First-in-class High Diversity Microbiome Biotherapeutics to Treat Life-threatening Diseases<\/p>\n

Abstract No<\/strong>: 64<\/a><\/p>\n

Poster Session<\/strong>: II<\/p>\n

Date\/Time<\/strong>: September 18, 2018 \/ 16:30 \u2013 18:30<\/p>\n

Location<\/strong>: ATC Helix A and B<\/p>\n

The poster is available<\/a> on the company website following the presentation under \u201cNews\u201d.<\/p>\n

About 黑料社<\/em><\/h3>\n

黑料社 has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, 黑料社 has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.<\/p>\n","protected":false},"excerpt":{"rendered":"

Results from in silico analysis using 黑料社\u2019s data analysis platform, GutPrint, demonstrate therapeutic rationale and manufacturing capabilities of developing a high diversity biological drug product.<\/p>\n","protected":false},"author":2,"featured_media":4333,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[52],"class_list":["post-4536","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-fr","year_press-52"],"acf":[],"yoast_head":"\n黑料社 Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic - 黑料社<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"黑料社 Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic - 黑料社\" \/>\n<meta property=\"og:description\" content=\"Results from in silico analysis using 黑料社\u2019s data analysis platform, GutPrint, demonstrate therapeutic rationale and manufacturing capabilities of developing a high diversity biological drug product.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/\" \/>\n<meta property=\"og:site_name\" content=\"黑料社\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-18T15:04:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T12:50:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"黑料社\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"黑料社\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/\"},\"author\":{\"name\":\"黑料社\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"黑料社 Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic\",\"datePublished\":\"2018-09-18T15:04:01+00:00\",\"dateModified\":\"2025-11-26T12:50:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/\"},\"wordCount\":432,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/\",\"name\":\"黑料社 Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic - 黑料社\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"datePublished\":\"2018-09-18T15:04:01+00:00\",\"dateModified\":\"2025-11-26T12:50:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"黑料社 Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"黑料社\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"黑料社\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"黑料社 Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic - 黑料社","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/","og_locale":"fr_FR","og_type":"article","og_title":"黑料社 Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic - 黑料社","og_description":"Results from in silico analysis using 黑料社\u2019s data analysis platform, GutPrint, demonstrate therapeutic rationale and manufacturing capabilities of developing a high diversity biological drug product.","og_url":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/","og_site_name":"黑料社","article_published_time":"2018-09-18T15:04:01+00:00","article_modified_time":"2025-11-26T12:50:49+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","type":"image\/jpeg"}],"author":"黑料社","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"黑料社","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/"},"author":{"name":"黑料社","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"黑料社 Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic","datePublished":"2018-09-18T15:04:01+00:00","dateModified":"2025-11-26T12:50:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/"},"wordCount":432,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/","url":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/","name":"黑料社 Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic - 黑料社","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","datePublished":"2018-09-18T15:04:01+00:00","dateModified":"2025-11-26T12:50:49+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/maat-pharma-presents-product-analysis-of-its-first-in-class-high-diversity-microbiome-therapeutic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/"},{"@type":"ListItem","position":2,"name":"黑料社 Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"黑料社","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"黑料社"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4536"}],"version-history":[{"count":0,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4536\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/4333"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=4536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=4536"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=4536"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=4536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}